Comparison of sirolimus-, paclitaxel-, and everolimus-eluting stent in unprotected left main coronary artery percutaneous coronary intervention  by Lee, Michael S. et al.
P.O. Box 2925 Riyadh – 11461KSA
Tel: +966 1 2520088 ext 40151
Fax: +966 1 2520718
Email: sha@sha.org.sa
URL: www.sha.org.sa
FU
LL
 L
EN
G
TH
 A
RT
IC
LE
Received 27 December 2012; revised 1 March 2013; accepted 2 March 2013.
Available online 14 March 2013
⇑ Corresponding author. Address: UCLA Medical Center, Adult Car-
diac Catheterization Laboratory, 10833 Le Conte Avenue, Rm A2-237
CHS, Los Angeles, CA 90095-1679, United States.
E-mail address: mslee@mednet.ucla.edu (M.S. Lee).Comparison of sirolimus-, paclitaxel-,
and everolimus-eluting stent in unprotected left
main coronary artery percutaneous coronary
interventionMichael S. Lee a,b,c,d,⇑, Ehtisham Mahmud a,b,c,d, Lawrence Ang a,b,c,d, Gentian Lluri a,b,c,d,
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a–dUnited States, ItalyObjectives: This retrospective study evaluated the outcomes of patients who underwent unprotected left main
coronary artery (ULMCA) percutaneous coronary intervention (PCI) with different types of drug-eluting stents (DES).
Background: The standard of care for patients with ULMCA is coronary artery bypass surgery. However, current
guidelines recommend PCI in clinical conditions where there is an increased risk of adverse surgical outcomes. Clin-
ical outcomes of patients undergoing ULMCA PCI with different types of drug-eluting stents (DES) are unknown.
Methods: Data from a multicenter international registry, which included 239 consecutive patients from four insti-
tutions who ULMCA PCI with DES, were collected.
Results: There were 42 patients receiving paclitaxel-eluting stent (PES), 158 patients receiving sirolimus-eluting
stent (SES), and 39 patients receiving everolimus-eluting stent (EES). There was no statistical difference in major
adverse cardiovascular events, cardiac death, myocardial infarction, target lesion revascularization, and stent throm-
bosis among PES, SES, and EES at 30 days and 1 year.
Conclusions: There are no differences in clinical events among patients receiving PES, SES, and EES for ULMCA
disease.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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The standard of care for patients with unpro-tected left main coronary artery (ULMCA)
disease is coronary artery bypass grafting (CABG).1016–7315  2012 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
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(PCI) guidelines state that ULMCA stenting canProduction and hosting by Elsevier
Table 1. Baseline Characteristics.
Total (N = 239) PES (N = 42) SES (N = 158) EES (N = 39) p value
Age 68.4 ± 11.3 68.9 ± 12.3 67.8 ± 11.0 69.9 ± 11.4 0.55
LVEF 55.1 ± 9.1 56.1 ± 6.1 55.3 ± 8.0 52.8 ± 14.2 0.21
Male gender (%) 72.4 78.6 73.4 61.5 0.20
Prior MI (%) 34.2 39.5 37.1 17.9 0.06
Prior PCI (%) 34.9 24.3 36.7 38.5 0.33
Hypertension (%) 88.0 87.5 93.5 66.7 <0.001
Dyslipidemia (%) 79.4 85.0 78.6 76.9 0.61
Diabetes mellitus (%) 29.7 31.6 27.0 38.5 0.36
IABP (%) 13.4 7.1 13.3 20.5 0.21
GP IIb/IIIa (%) 15.5 14.6 16.4 12.8 0.84
Bifurcation (%) 72.8 81.0 73.4 61.5 0.14
Stent number 1.6 ± 0.7 1.5 ± 0.6 1.7 ± 0.6 0.9 ± 0.2 0.28
Stent diameter (mm) 3.5 ± 0.4 3.6 ± 0.5 3.3 ± 0.3 3.9 ± 0.5 <0.001
Stent length (mm) 17.7 ± 9.2 17.6 ± 9.9 16.7 ± 8.7 21.7 ± 9.8 0.009
Values are shown as mean ± SD or percentages where appropriate. EES = everolimus-eluting stent; IABP = intra-aortic balloon pump; GP = Glyco-
protein; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting
stent; SES = sirolimus-eluting stent.
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Table 2. 30-Days Outcomes.
(%) Total (N = 239) PES (N = 42) SES (N = 158) EES (N = 39) p value
MACE 0.4 0.0 0.6 0.0 0.77
Death 0.4 0.0 0.6 0.0 0.77
MI 0.0 0.0 0.0 0.0 >0.9
TLR 0.0 0.0 0.0 0.0 >0.9
Stent thrombosis 0.0 0.0 0.0 0.0 >0.9
EES = Everolimus-eluting stent; MACE = Major adverse cardiovascular events; MI = Myocardial infarction; PES = Paclitaxel-eluting stent;
SES = Sirolimus-eluting stent; TLR = Target lesion revascularization.
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Bare metal stents (BMS) are associated with high
rates of restenosis and frequent rates of reinter-
vention [3]. Drug-eluting stents (DES) decrease
the rate of restenosis compared to BMS [4,5].
Data on ULMCA PCI with DES are based on
studies with first-generation DES. There are only
limited data with regard to second-generation
DES for ULMCA disease. We report on the out-
comes of ULMCA PCI with paclitaxel-eluting
stents (PES), sirolimus-eluting stents (SES), and
everolimus-eluting stents (EES).Methods
This was a multicenter, non-randomized retro-
spective study of 239 consecutive patients with
ULMCA disease who received PES (Taxus, Boston
Scientific Corporation, Natick, Massachusetts),
SES (Cypher, Cordis, Johnson & Johnson Corpo-
ration, Miami, Florida), or EES (Xience, Abbot
Vascular, Santa Clara, CA, also distributed as
Promus; Boston Scientific), during the 2003–2011
period. Baseline demographic, procedural, angio-
graphic, and clinical outcomes were collected
and analyzed from UCLA Medical Center, UCSD
Medical Center, University of Turin, and SantaBarbara Cottage Hospital. The Institutional Re-
view Board for each institution approved the use
of the database review for the study.
PCI was performed with standard techniques
and all patients received at least 300 mg of
aspirin and loading dose of clopidogrel 300–
600 mg. The choice of anticoagulation was at the
discretion of the operator. All patients continued
to take at least 80 mg of aspirin and 75 mg of clop-
idogrel for a minimum of 1 year after PCI. The
type of stent was period dependent and operator
dependent. The clinical data includes patients
who underwent PCI of the LM with or without
PCI of other vessels. The type of stenting tech-
nique for bifurcation lesions was left to the discre-
tion of the operator.
The primary endpoint was major adverse car-
diovascular events (MACE), as defined by death,
myocardial infarction (MI), and target lesion
revascularization (TLR). Death was considered
cardiac unless an unequivocal non-cardiac cause
was identified. MI was diagnosed by the presence
of ischemic signs or symptoms plus significant
new Q waves on electrocardiogram or elevation
of cardiac markers. TLR was defined as repeat
revascularization with either CABG or PCI be-
cause of restenosis within the stent or in the
Table 3. 1-Year outcomes.
(%) Total (N = 239) PES (N = 42) SES (N = 158) EES (N = 39) p value
MACE 13.0 14.3 13.9 7.7 0.56
Death 2.9 7.1 1.9 2.6 0.20
MI 3.8 4.8 3.2 5.1 0.79
TLR (%) 7.5 2.4 9.5 5.1 0.25
Stent thrombosis 1.3 4.8 0.6 0.0 0.08
EES = everolimus-eluting stent; MACE = major adverse cardiovascular events; MI = myocardial infarction; PES = paclitaxel-eluting stent;
SES = sirolimus-eluting stent; TLR = target lesion revascularization.
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PES VS. SES VS. EES IN LEFT MAIN PCI5 mm proximal or distal segments. The Academic
Research Consortium definition for definite or
probable stent thrombosis was used [6].
Continuous variables are presented as
mean ± SD. Categorical variables are presented
as percentages and compared by ANOVA test.
Statistical analysis was performed with SPSS ver-
sion 20.0 (SPSS, INC., Chicago, Illinois). A value of
p < 0.05 was considered statistically significant.Results
Of the 239 patients who underwent ULMCA PCI
with DES, 42 patients received PES, 158 patients
received SES, and 39 patients received EES. All
three groups were well matched for baseline char-
acteristics including age, sex, hyperlipidemia, and
diabetes except hypertension, as patients receiv-
ing EES were less likely to have hypertension
(Table 1). Patients receiving EES also had larger
stent diameter and length.
The clinical event rates were very low in the
three groups at 30 days with only one death in the
SES group (Table 2). At 1 year, there was no signif-
icant difference in MACE (PES 14.3% vs SES 13.9%
vs EES 7.7%, p = 0.56), death (PES 7.1% vs SES
1.9% vs EES 2.6%, p = 0.20), myocardial infarction
(PES 4.8% vs SES 3.2% vs EES 5.1%, p = 0.79),
and target lesion revascularization (PES 2.4% vs
SES 9.5% vs EES 5.1%, p = 0.25) (Table 3). There
was a trend towards increased stent thrombosis
with PES (4.8% vs SES 0.6% vs EES 0%, p = 0.08).Discussion
The main finding of this multicenter, interna-
tional registry is that in patients treated with PCI
for ULMCA disease, there were no significant dif-
ferences in the primary outcomes among PES,
SES, and EES. In addition, our study suggests that
DES appear to be safe, associated with low rates of
death, MI, and stent thrombosis.
Initial studies comparing DES and BMS for
ULMCA PCI showed less MACE with DES, mainly
due to a reduction in TLR [7]. However, some stud-ies suggest that the second-generation DES to be
approved has demonstrated superiority over
first-generation DES by reducing death or MI [8].
Several studies have evaluated the clinical out-
comes of ULMCA PCI. In the SYNTAX trial, the
rate of MACE or cerebrovascular events at
12 months in the ULMCA subset was similar in
the CABG and PCI groups, 13.7% and 15.8%,
respectively. Furthermore, the higher rate of re-
peat revascularization among patients with ULM-
CA disease in the PCI groups (11.8% vs 6.5%) was
offset by a higher rate of stroke in the CABG
group (2.7% vs 0.3%) [9]. In addition, a meta-anal-
ysis study comparing CABG with PCI with DES
for ULMCA disease did not demonstrate a signif-
icant difference between the CABG and DES in
the risk for death, MI, or stroke [10].
There is a paucity of data with second genera-
tion DES for ULMCA disease. It may be difficult
to demonstrate a difference in clinical events
because the large caliber of the ULMCA requires
more neointimal hyperplasia to result in resteno-
sis [11]. In the ISAR-LEFT-MAIN trial, the 1-year
TLR rate was 7.8% and 6.5% with SES and PES,
respectively [12]. In our study, the small number
of patients with no required angiography could
explain the 0% TLR rate. PES had similar results
with EES in ULMCA PCI at 3 years [13]. In our
study, the rates of death and stent thrombosis
were numerically high with PES. One potential
reason for this observation may be due to more
distal bifurcation lesions (81% vs. SES 73% vs.
EES 62%) that were treated with more stents
(1.5% vs. SES 0.6% vs. EES 0.9%). However, the
differences in these baseline characteristics were
not statistically significant. Another reason may
be the improved biocompatibility of the fluoro-
polymer in the EES, resulting in less hypersensi-
tivity, inflammation of the endothelial layer, and
stent thrombosis.
The small number of patients receiving PES and
EES is a limitation to draw firm conclusions on any
differences among these stent types. This can
explain the difference of stent thrombosis, which
appears to be higher in patients receiving PES.
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any differences in the individual components of
the composite outcome. Another limitation of this
study is the nonrandomized design and the short
duration of follow-up.Conclusions
There are no differences in clinical events
among patients receiving PES, SES, and EES for
ULMCA disease. Large prospective randomized
trials are needed to compare the long-term safety
and efficacy of different types of DES.References
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